USPTO serial 85390392
CHANTILLY BIOPHARMA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- HARDY LUDLOW, TARAH KIM
- Law office
- TMO LAW OFFICE 110 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with CHANTILLY BIOPHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Analgesic and muscle relaxant pharmaceutical preparations; Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; Antimicrobial preservatives for cosmetics and pharmaceuticals; Astringents; Balms for pharmaceutical purposes; Cardiovascular pharmaceuticals; Cellulose esters for pharmaceutical purposes; Cellulose ethers for pharmaceutical purposes; Charcoal for pharmaceutical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for active pharmaceuticals; Dermatological pharmaceutical products; Digestives for pharmaceutical purposes; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of a coating for pharmaceutical actives that facilitate the delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Ferments for pharmaceutical purposes; Gelatin capsules sold empty for pharmaceuticals; Homeopathic pharmaceuticals for use in the treatment of colds and the flu; Hyaluronic acid for pharmaceutical purposes; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Inhalers filled with pharmaceutical actives; Injectable pharmaceuticals for treatment of anaphylactic reactions; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Ocular pharmaceuticals; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension | ACTIVE | Mar 20, 2011 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 5, 2012 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 5, 2012 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 8, 2011 | CEPE | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED | — |
| Dec 8, 2011 | ALIE | ASSIGNED TO LIE | — |
| Dec 8, 2011 | GEAN | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Dec 8, 2011 | GEAP | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Dec 8, 2011 | CPEA | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED | — |
| Nov 30, 2011 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 10, 2011 | MPMK | NOTICE OF PSEUDO MARK MAILED | — |
| Aug 9, 2011 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 9, 2011 | NWAP | NEW APPLICATION ENTERED | — |